Unique ID issued by UMIN | UMIN000058788 |
---|---|
Receipt number | R000067219 |
Scientific Title | The effect of respiratory viral infection on exacerbation of bronchiectasis: a prospective cohort study |
Date of disclosure of the study information | 2025/08/14 |
Last modified on | 2025/08/13 14:10:39 |
The effect of respiratory viral infection on exacerbation of bronchiectasis: a prospective cohort study
The effect of respiratory viral infection on exacerbation of bronchiectasis: a prospective cohort study
The effect of respiratory viral infection on exacerbation of bronchiectasis: a prospective cohort study
The effect of respiratory viral infection on exacerbation of bronchiectasis: a prospective cohort study
Japan |
Bronchiectasis and respiratory viral infections
Pneumology | Infectious disease |
Others
NO
The objective of this prospective cohort study of patients with bronchiectasis is to clarify the detection status of respiratory viruses during stable and exacerbation periods and their impact on clinical outcomes.
Others
The objective of this prospective cohort study of patients with bronchiectasis is to clarify the detection status of respiratory viruses during stable and exacerbation periods and their impact on clinical outcomes.
Exploratory
The primary endpoint will be calculated as the odds ratio of respiratory virus detection rates by type during exacerbations and during stable periods.
In the secondary endpoints, we will compare the clinical characteristics of viral positive exacerbations and negative exacerbations (temporal changes in inflammatory markers, respiratory function, and quality of life scores [Quality of Life-Bronchiectasis; QOL-B], exacerbation frequency according to the severity of bronchiectasis [Bronchiectasis Severity Index; BSI], and frequency of severe exacerbations). Additionally, we will perform similar analyses for each viral strain.
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Patients with bronchiectasis who are 18 years of age or older, have had no exacerbations in the past 4 weeks, and have provided informed consent to participate in this study are eligible for inclusion. The diagnosis of bronchiectasis is based on chest HRCT findings of bronchiectasis and the presence of two of the following clinical symptoms: cough, sputum production, or a history of exacerbations.
Patients with cystic fibrosis, active tuberculosis, AIDS, those currently taking immunosuppressive drugs, those currently receiving systemic steroid therapy (equivalent to 20 mg/day or more of prednisolone on a daily basis), malignant tumors, or pulmonary fibrosis (traction bronchiectasis) are excluded.
100
1st name | Mitsuru |
Middle name | |
Last name | Sada |
Kyorin University Hospital
Department of Respiratory Medicine
181-8611
6-20-2 shinkawa, Mitaka, Tokyo 181-8611, Japan
+81-422-47-5511
rainbow_orch@ks.kyorin-u.ac.jp
1st name | Tatsuya |
Middle name | |
Last name | Shirai |
Japan Institute for Health Security
Department of Respiratory Viruses
208-0011
4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan
+81-42-561-0771
shirai@niid.go.jp
Kyorin University Hospital
Japan Agency for Medical Research and Development (AMED)
Other
Japan Institute for Health Security
Kyorin University
6-20-2 shinkawa, Mitaka, Tokyo 181-8611, Japan
+81-422-47-5511
rec@ks.kyorin-u.ac.jp
NO
2025 | Year | 08 | Month | 14 | Day |
Unpublished
Preinitiation
2025 | Year | 08 | Month | 13 | Day |
2025 | Year | 09 | Month | 01 | Day |
2030 | Year | 03 | Month | 31 | Day |
Prospective study
2025 | Year | 08 | Month | 13 | Day |
2025 | Year | 08 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067219